Advertisement
Advertisement
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
38.73
USDSponsored
+3.88
+11.13%
May 08, 16:00 UTC -4
Closed
After-Market
38.72
-0.01
-0.03%
NAMS Earnings Reports
Positive Surprise Ratio
NAMS beat 6 of 11 last estimates.
55%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.27M
/-$0.51
Implied change from Q1 26 (Revenue/ EPS)
-58.20%
/+27.50%
Implied change from Q2 25 (Revenue/ EPS)
-93.36%
/+240.00%
NewAmsterdam Pharma Company N.V. Ordinary Shares earnings per share and revenue
On May 07, 2026, NAMS reported earnings of -0.40 USD per share (EPS) for Q1 26, beating the estimate of -0.50 USD, resulting in a 20.32% surprise. Revenue reached 3.04 million, compared to an expected 875.50 thousand, with a 247.23% difference. The market reacted with a +12.46% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.51 USD, with revenue projected to reach 1.27 million USD, implying an increase of 27.50% EPS, and decrease of -58.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Quoin Pharmaceuticals, Ltd. - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.96
Actual
-$1.77
Surprise
+9.93%
FAQ
What were NewAmsterdam Pharma Company N.V. Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, NewAmsterdam Pharma Company N.V. Ordinary Shares reported EPS of -$0.40, beating estimates by 20.32%, and revenue of $3.04M, 247.23% above expectations.
How did the market react to NewAmsterdam Pharma Company N.V. Ordinary Shares's Q1 2026 earnings?
The stock price moved up 12.46%, changed from $30.99 before the earnings release to $34.85 the day after.
When is NewAmsterdam Pharma Company N.V. Ordinary Shares expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for NewAmsterdam Pharma Company N.V. Ordinary Shares's next earnings report?
Based on 10
analysts, NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to report EPS of -$0.51 and revenue of $1.27M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement